<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389061</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 16.06</org_study_id>
    <nct_id>NCT03389061</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet</brief_title>
  <acronym>CRUSADE-1</acronym>
  <official_title>Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EpclusaÂ® is a pan-genotypic, once-daily tablet for the treatment of chronic hepatitis C virus&#xD;
      (HCV) infection containing the NS5B- polymerase inhibitor sofosbuvir (SOF, nucleotide&#xD;
      analogue) 400 mg and the NS5A inhibitor velpatasvir (VEL) 100 mg.&#xD;
&#xD;
      For patients with swallowing difficulties, administration of whole tablets can be&#xD;
      problematic. In addition, HCV patients that are hospitalized (at intensive care units) due to&#xD;
      severe illness (co-infections/ liver failure) might not be able to swallow medication.&#xD;
      Therefore it is useful to know whether it is possible to administer SOF/VEL through a&#xD;
      different route, like a feeding tube.&#xD;
&#xD;
      In daily practice, information about the safety and efficacy of crushed tablets is lacking&#xD;
      which might result in interruption or discontinuation of expensive HCV therapy. However, it&#xD;
      is not recommended to interrupt treatment because there is no evidence about the efficacy of&#xD;
      the therapy after discontinuation (and restart).&#xD;
&#xD;
      Currently, patients and healthcare professionals are crushing SOF/VEL tablets without&#xD;
      information about efficacy and safety. Depending on the biopharmaceutical characteristics of&#xD;
      a drug formulation, crushing tablets can lead to altered pharmacokinetics of drugs.&#xD;
&#xD;
      It is important to know whether pharmacokinetic parameters are influenced by crushing of&#xD;
      tablets; both a decrease and an increase in exposure may occur. A decrease of the plasma&#xD;
      concentrations of SOF and/or VEL potentially reduces the therapeutic effect of the drugs.&#xD;
      Higher doses or switching to other HCV-drugs might be needed. In contrast, in case a higher&#xD;
      Cmax,ss and/or exposure occurs there might be an increased risk of toxicity.&#xD;
&#xD;
      As a result, crushing the drug is a contra-indication based on the available data.&#xD;
&#xD;
      Therefore this study will be conducted to investigate whether a crushed SOF/VEL tablet is&#xD;
      bioequivalent to SOF/VEL as a whole tablet.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of patients who are eligible for inclusion: less patients on treatment and not using&#xD;
    epclusa.&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">March 22, 2019</completion_date>
  <primary_completion_date type="Actual">March 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Bio-equivalence Study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 24 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>one dosing interval after administration of SOF/VEL (up to 24 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During the entire conduct of the study, maximum of two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HCV</condition>
  <arm_group>
    <arm_group_label>sofosbuvir/velpatasvir tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sofosbuvir/velpatasvir crushed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose crushed sofosbuvir/velpatasvir in a fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir/velpatasvir tablet</intervention_name>
    <description>Single-dose SOF/VEL as a whole tablet in a fasted state.</description>
    <arm_group_label>sofosbuvir/velpatasvir tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir/velpatasvir crushed</intervention_name>
    <description>Single-dose crushed SOF/VEL in a fasted state.</description>
    <arm_group_label>sofosbuvir/velpatasvir crushed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with SOF/VEL treatment for the treatment of chronic HCV genotype 1 through 6.&#xD;
&#xD;
          2. Patient is at least 18 at the day of screening.&#xD;
&#xD;
          3. Patient is able and willing to sign the Informed Consent Form.&#xD;
&#xD;
          4. Patient is able and willing to follow protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant female (as confirmed by an hCG urine test performed at screening) or&#xD;
             breast-feeding female.&#xD;
&#xD;
          2. Relevant history or current condition that might interfere with drug absorption,&#xD;
             distribution, metabolism or excretion.&#xD;
&#xD;
          3. Inability to understand the nature and extent of the study and the procedures&#xD;
             required.&#xD;
&#xD;
          4. Clinically relevant low hemoglobin concentration at screening judged by the patient's&#xD;
             own hepatologist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Bonn, Germany</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center Department of GI tract</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>van Seyen M, Samson AD, Cullen L, Eastick K, Knol H, Colbers A, Burger DM. Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder. Int J Antimicrob Agents. 2020 Jun;55(6):105934. doi: 10.1016/j.ijantimicag.2020.105934. Epub 2020 Mar 7.</citation>
    <PMID>32156618</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epclusa</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Crushing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crush Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

